The role of SGLT2 inhibitors beyond glucose-lowering to cardio-renal protection

The role of SGLT2 inhibitors beyond glucose-lowering to cardio-renal protection

People with type 2 diabetes mellitus (T2DM) are at high risk of developing cardiovascular disease (CVD) and kidney disease. This enhanced cardio-renal risk persists despite improvements in care and treatments over the last 20 years. Intensive glucose control alone does not substantially reduce the r...

Full description

Bibliographic Details
Main Author:	J. Karalliedde
Format:	Article
Language:	Russian
Published:	«FIRMA «SILICEA» LLC 2021-04-01
Series:	Российский кардиологический журнал
Subjects:	cardiovascular disease hospitalization for heart failure end stage kidney disease
Online Access:	https://russjcardiol.elpub.ru/jour/article/view/4323

Similar Items

Retrospective analysis of SGLT2 inhibitors in heart failure with preserved ejection fraction
by: John S. Clemmer, et al.
Published: (2023-06-01)

Dramatic disease regression in a case of HFrEF with end‐stage renal failure treated with sacubitril/valsartan and SGLT2i
by: Massimo Mapelli, et al.
Published: (2023-06-01)

Editorial: Recent advancement of the cardio-renal protective effects of SGLT2 inhibitors in people with and without diabetes
by: Satoru Kuriyama, et al.
Published: (2023-10-01)

Myocardial Cytoskeletal Adaptations in Advanced Kidney Disease
by: Arvin Halim, et al.
Published: (2022-03-01)

Risk prediction modeling for cardiorenal clinical outcomes in patients with non-diabetic CKD using US nationwide real-world data
by: Christoph Wanner, et al.
Published: (2025-01-01)

Efficacy and Safety of the Use of SGLT2 Inhibitors in Patients on Incremental Hemodialysis: Maximizing Residual Renal Function, Is There a Role for SGLT2 Inhibitors?
by: José C. De La Flor, et al.
Published: (2023-07-01)

Exploring SGLT-2 Inhibitors: Benefits beyond the Glucose-Lowering Effect—What Is New in 2023?
by: Clipper F. Young, et al.
Published: (2023-09-01)

Major cardiovascular events and associated factors among routine hemodialysis patients with end-stage renal disease at tertiary care hospital in Somalia
by: Mohamed Farah Yusuf Mohamud, et al.
Published: (2023-05-01)

Estimating the population-level impacts of improved uptake of SGLT2 inhibitors in patients with chronic kidney disease: a cross-sectional observational study using routinely collected Australian primary care dataResearch in context
by: Brendon L. Neuen, et al.
Published: (2024-02-01)

ISCHEMIC HEART DISEASE AND RENAL DYSFUNCTION
by: F. I. Belyalov
Published: (2017-07-01)

SGLT2 Inhibitors: Nephroprotective Efficacy and Side Effects
by: Carlo Garofalo, et al.
Published: (2019-06-01)

SGLT2 Inhibitors: The Next Blockbuster Multifaceted Drug?
by: Jonathan C. H. Chan, et al.
Published: (2023-02-01)

SGLT2 inhibitors: Beyond glycemic control
by: Irtiza Hasan, et al.
Published: (2024-03-01)

Management of Cardiovascular Diseases in Chronic Hemodialysis Patients
by: Zhen Zhang, et al.
Published: (2023-06-01)

Incident heart failure and the subsequent risk of progression to end stage kidney disease in individuals with type 2 diabetes
by: Sylvia Liu, et al.
Published: (2024-06-01)

Evolution of sodium-glucose co-transporter 2 inhibitors from a glucose-lowering drug to a pivotal therapeutic agent for cardio-renal-metabolic syndrome
by: Hiroki Akiyama, et al.
Published: (2023-01-01)

Real-life underuse of SGLT2 inhibitors for patients with type 2 diabetes at high cardiorenal risk
by: André J. Scheen
Published: (2024-01-01)

New insights into the cardio-renal benefits of SGLT2 inhibitors and the coordinated role of miR-30 family
by: Abdellatif El Khayari, et al.
Published: (2024-11-01)

Exploring the Cardiorenal Benefits of SGLT2i: A Comprehensive Review
by: Angelica Cersosimo, et al.
Published: (2024-10-01)

Predictors of cardiovascular disease in peritoneal dialysis patients: A Prospective longitudinal cohort study
by: I. Shifris, et al.
Published: (2022-11-01)

Indirect comparison of SGLT2 inhibitors in patients with established heart failure: evidence based on Bayesian methods
by: Hai‐Bin Chen, et al.
Published: (2023-04-01)

Cardiovascular protection by SGLT2 inhibitors – Do anti-inflammatory mechanisms play a role?
by: Asmaa Elrakaybi, et al.
Published: (2022-10-01)

Impact of end stage renal disease on the clinical outcomes of diabetics admitted for heart failure: Analysis of national inpatient sample
by: Muhammad Usman Almani, et al.
Published: (2023-03-01)

Editorial: CaRe Me: improving the cardio-renal-metabolic care of patients through clinical and translational research
by: José Jesús Broseta, et al.
Published: (2024-07-01)

Incident heart failure and the subsequent risk of progression to end stage kidney disease in individuals with type 2 diabetes
by: Liu, Sylvia, et al.
Published: (2024)

Impact of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Renal Function in Patient with Heart Failure
by: Teruhiko Imamura, et al.
Published: (2021-12-01)

The Role of Omentin-1 in Cardio-renal Syndrome
by: Nagham Q. Kazim, et al.
Published: (2016-03-01)

Editorial: Clinical prospective of SGLT2 inhibitors in atherosclerosis
by: Annalisa Capuano, et al.
Published: (2022-11-01)

Aging is associated with slower renal progression in patients with chronic kidney disease
by: Chia-Tse Yeh, et al.
Published: (2022-01-01)

Oral Anticoagulant Initiation in Patients With Kidney Failure on Hemodialysis Newly Diagnosed With Atrial Fibrillation (2007-2020): An Observational Study of Trends and Disparities
by: Wolfgang C. Winkelmayer, et al.
Published: (2025-02-01)

Lactobacilli species diversity in gut microbiota of renal failure patients
by: Gholamreza Hanifi, et al.
Published: (2020-06-01)

Nursing Home Status Adjustment for Standardized Mortality and Hospitalization in Dialysis Facility ReportsPlain-Language Summary
by: Shu Chen, et al.
Published: (2023-02-01)

The New Role of SGLT2 Inhibitors in the Management of Heart Failure: Current Evidence and Future Perspective
by: Saverio Muscoli, et al.
Published: (2022-08-01)

Association of very Low-density Lipoprotein Cholesterol with All-cause and Cardiovascular Mortality in Peritoneal Dialysis
by: Xishao Xie, et al.
Published: (2017-03-01)

Cardiac Imaging and Management of Cardiac Disease in Asymptomatic Renal Transplant Candidates: A Current Update
by: Eirini Lioudaki, et al.
Published: (2022-09-01)

Safety and efficacy of oxycodone for refractory dyspnea in end-stage heart failure patients with chronic kidney disease: a case series of eight patients
by: Masayuki Tanaka, et al.
Published: (2024-10-01)

Prognostic Value of Hemoglobin Concentration on Renal Outcomes with Diabetic Kidney Disease: A Retrospective Cohort Study [Letter]
by: Chao CT
Published: (2024-04-01)

SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain
by: Bartosz Rolek, et al.
Published: (2023-07-01)

The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection
by: Emily Brown, et al.
Published: (2021-01-01)

Metabolic reprogramming as the basis for sodium-glucose co-transporter type 2 inhibitors cardio- and nephroprotective effect
by: O N. Kurochkina, et al.
Published: (2024-06-01)